Abstract 226P
Background
Urothelial carcinoma (UC) has a highly complex genomic landscape. With the spread of immunotherapy, accurate stratification strategies are needed. As cancer tissues are now frequently screened for specific sets of mutations, a large number of samples has become available for analysis. Classification of patients with similar mutation profiles may help identifying subgroups of patients outcomes. However, classification based on somatic mutations is challenging due to the sparseness and heterogeneity of the data.
Methods
A retrospective study was performed to identify the prognosis-related somatic mutations from 192 UC in The Cancer Genome Atlas (TCGA) database. Cox regression were performed to screen out prognostic genes.
Results
A total of 176 genes were related with immuno-survival. Then, a stepwise multivariate Cox regression analysis was performed, and 14 gene were selected to establish a predictive model. Compared with the wildtype group, the patients with mutated signature had unfavorable to prognosis (p<0.001). ROC curve analysis demonstrated the predictive ability for 1-, 3-, 5-, and 10-year OS, with areas under the curve (AUCs) of 0.7684, 0.667,0.619 and 0.647, respectively. In mutated signature cohorts, the five most frequently mutated genes were TP53 (50%), KMT2D (43%), LRP1B (33%), PER1 (33%), and RNF213 (33%). Dissimilarly, the five most frequently mutated genes were TP53 58%), ARID1A (29%), KMT2D (29%), RNF213 (27%), and KDM6A (26%) in wildtype cohorts, which may imply that different characteristic states have different molecular mechanisms.
Conclusions
These data underline the potential value of using somatic mutations to accurately stratify UC patients into clinically actionable subgroups. This model could reduce overtreatment in UC patients with mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract